ENGENE HOLDINGS INC (ENGN)

CA29286M1059 - Common Stock

5.83  -0.13 (-2.18%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ENGN. ENGN was compared to 568 industry peers in the Biotechnology industry. While ENGN seems to be doing ok healthwise, there are quite some concerns on its profitability. ENGN is valued expensive and it does not seem to be growing.



2

1. Profitability

1.1 Basic Checks

ENGN had negative earnings in the past year.
In the past year ENGN has reported a negative cash flow from operations.

1.2 Ratios

With an excellent Return On Assets value of -14.70%, ENGN belongs to the best of the industry, outperforming 82.48% of the companies in the same industry.
The Return On Equity of ENGN (-17.03%) is better than 87.26% of its industry peers.
Industry RankSector Rank
ROA -14.7%
ROE -17.03%
ROIC N/A
ROA(3y)-49.41%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ENGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, ENGN has about the same amount of shares outstanding.
There is no outstanding debt for ENGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ENGN has an Altman-Z score of 4.29. This indicates that ENGN is financially healthy and has little risk of bankruptcy at the moment.
ENGN has a better Altman-Z score (4.29) than 79.11% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that ENGN is not too dependend on debt financing.
ENGN has a worse Debt to Equity ratio (0.09) than 64.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 4.29
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 19.52 indicates that ENGN has no problem at all paying its short term obligations.
ENGN's Current ratio of 19.52 is amongst the best of the industry. ENGN outperforms 95.22% of its industry peers.
A Quick Ratio of 19.52 indicates that ENGN has no problem at all paying its short term obligations.
ENGN has a better Quick ratio (19.52) than 95.22% of its industry peers.
Industry RankSector Rank
Current Ratio 19.52
Quick Ratio 19.52

0

3. Growth

3.1 Past

The earnings per share for ENGN have decreased strongly by -263.86% in the last year.
EPS 1Y (TTM)-263.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENGN. In the last year negative earnings were reported.
Also next year ENGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ENGN!.
Industry RankSector Rank
Dividend Yield N/A

ENGENE HOLDINGS INC

NASDAQ:ENGN (12/20/2024, 8:07:12 PM)

5.83

-0.13 (-2.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-10 2024-09-10/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change4.67%
Ins OwnersN/A
Ins Owner Change6.21%
Market Cap297.21M
Analysts86.67
Price Target28.9 (395.71%)
Short Float %N/A
Short Ratio5.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.93%
Min EPS beat(2)-42.19%
Max EPS beat(2)16.34%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.75%
PT rev (3m)-12.82%
EPS NQ rev (1m)-0.79%
EPS NQ rev (3m)-1.32%
EPS NY rev (1m)3.24%
EPS NY rev (3m)8.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-1.68
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0
BVpS4.52
TBVpS4.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.7%
ROE -17.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.41%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 285.47%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.52
Quick Ratio 19.52
Altman-Z 4.29
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)112.39%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-263.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.99%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-352.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3090.41%
EBIT Next 3Y-289.51%
EBIT Next 5YN/A
FCF growth 1Y-4042.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3867.59%
OCF growth 3YN/A
OCF growth 5YN/A